Loading…
Reported covered position: Staff, Senator Bill Frist (1998-2004)
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Safeguarding America's Pharmaceuticals Act of 2011
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
Perscription Drug User Fee Act Reauthorization FDA funding and agency effectiveness Drug importation issues Safeguarding America's Pharmaceuticals Act of 2011- H.R. 3026
Safeguarding America's Pharmaceuticals Act of 2011
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
Perscription Drug User Fee Act Reauthorization FDA funding and agency effectiveness Drug importation issues Safeguarding America's Pharmaceuticals Act of 2011- H.R. 3026
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
AMYLIN PHARMACEUTICALS via AMYLIN PHARMACEUTICALS
2012 · third_quarter · 3T
Issues related to prevention, diagnosis and treatment of diabetes
Issues relating to Medicare Part D rebates
FDA funding and agency effectiveness Potential Super Committee legislation affecting Medciare Part D and Medicaid rebates
Source: Senate LDA
Safeguarding America's Pharmaceuticals Act of 2011
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
Perscription Drug User Fee Act Reauthorization FDA funding and agency effectiveness Drug importation issues Safeguarding America's Pharmaceuticals Act of 2011- H.R. 3026
Safeguarding America's Pharmaceuticals Act of 2011
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
Perscription Drug User Fee Act reauthorization FDA funding and agency effectiveness Drug importation issues Safeguarding America's Pharmaceuticals Act of 2011- H.R. 3026
Safeguarding America's Pharmaceuticals Act of 2011
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
Perscription Drug User Fee Act Reauthorization FDA funding and agency effectiveness Drug importation issues Safeguarding America's Pharmaceuticals Act of 2011- H.R. 3026
Exclusivity, damages and estoppel provisions in the Patent Reform Act of 2009 (S. 515, H.R. 1260)
Exclusivity, damages and estoppel provisions in the Patent Reform Act of 2009 (S. 515, H.R. 1260)
Exclusivity, damages and estoppel provisions in the Patent Reform Act of 2009 (S. 515, H.R. 1260)
Exclusivity, damages and estoppel provisions in the Patent Reform Act of 2009 (S. 515, H.R. 1260)
Exclusivity, damages and estoppel provisions in the Patent Reform Act of 2009 (S. 515, H.R. 1260)
Exclusivity, damages and estoppel provisions in the Patent Reform Act of 2009 (S. 515, H.R. 1260)
Exclusivity, damages and estoppel provisions in the Patent Reform Act of 2009 (S. 515, H.R. 1260)
Exclusivity, damages and estoppel provisions in the Patent Reform Act of 2009 (S. 515, H.R. 1260)
Exclusivity, and damanges provisions in the Patent Reform Act of 2009 (S. 515, H.R. 1260)
Exclusivity, damanges and estoppel provisions in the Patent Reform Act of 2009 (S. 515, H.R. 1260)
Exclusivity, and damanges provisions in the Patent Reform Act of 2009 (S. 515, H.R. 1260)
Promoting Innovation and Access to Life-Saving Medicine Act
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
Data exclusivity provisions in H.R. 1548, Pathway for Biosimilars Act Data eclsuivity provisions in Promoting Innovation and Access to Life-Saving Medicine Act (H.R. 1427,S. 726) Physician Payments Sunshine provision of H.R. 3200 America's Affordable Health Choices Act of 2009 FDA Risk Evaulation Mitigation Strategies (REMS) Drug Safety Communications Drug importation issues
Promoting Innovation and Access to Life-Saving Medicine Act
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
Data exclusivity provisions in H.R. 1548, Pathway for Biosimilars Act Data eclsuivity provisions in Promoting Innovation and Access to Life-Saving Medicine Act (H.R. 1427,S. 726) Physician Payments Sunshine provision of H.R. 3200 America's Affordable Health Choices Act of 2009 FDA Risk Evaulation Mitigation Strategies (REMS) Drug Safety Communications Drug importation issues
Data exclusivity provisions in H.R. 1548, Pathway for Biosimilars Act Data eclsuivity provisions in Promoting Innovation and Access to Life-Saving Medicine Act (H.R. 1427,S. 726) Physician Payments Sunshine provision of H.R. 3200 America's Affordable Health Choices Act of 2009 FDA Risk Evaulation Mitigation Strategies (REMS) Drug Safety Communications Drug importation issues
Data exclusivity provisions in H.R. 1548, Pathway for Biosimilars Act Data eclsuivity provisions in Promoting Innovation and Access to Life-Saving Medicine Act (H.R. 1427,S. 726) Physician Payments Sunshine provision of H.R. 3200 America's Affordable Health Choices Act of 2009 FDA Risk Evaulation Mitigation Strategies (REMS) Drug Safety Communications Drug importation issues
Comparative Effectiveness Research Act of 2009
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
Medicare provisions and Medicaid rebate issues in S. 1679, the Affordable Health Choices Act; America's Healthy Futures Act of 2009 (no bill number); H.R. 3200 America's Affordable Health Choices Act of 2009 H.R. 2502 Comparative Effectiveness Research Act of 2009 S. 1213 Patient Centered Outcomes Research Act of 2009 Provisions related to comparative effectiveness reserach and reimbursement in S. 1679, the Affordable Health Choices Act; America's Healthy Futures Act of 2009 (no bill number); H.R. 3200 America's Affordable Health Choices Act of 2009
Comparative Effectiveness Research Act of 2009
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
Chronic disease and diabetes care related provisions in S. 1679, the Affordable Health Choices Act; America's Healthy Futures Act of 2009 (no bill number); H.R. 3200 America's Affordable Health Choices Act of 2009 H.R. 2502 Comparative Effectiveness Research Act of 2009 S. 1213 Patient Centered Outcomes Research Act of 2009 Provisions related to comparative effectiveness reserach and reimbursement in S. 1679, the Affordable Health Choices Act; America's Healthy Futures Act of 2009 (no bill number); H.R. 3200 America's Affordable Health Choices Act of 2009
Comparative Effectiveness Research Act of 2009
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
Medicare provisions and Medicaid rebate issues in S. 1679, the Affordable Health Choices Act; America's Healthy Futures Act of 2009 (no bill number); H.R. 3200 America's Affordable Health Choices Act of 2009 H.R. 2502 Comparative Effectiveness Research Act of 2009 S. 1213 Patient Centered Outcomes Research Act of 2009 Provisions related to comparative effectiveness reserach and reimbursement in S. 1679, the Affordable Health Choices Act; America's Healthy Futures Act of 2009 (no bill number); H.R. 3200 America's Affordable Health Choices Act of 2009
Comparative Effectiveness Research Act of 2009
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
Comparative Effectiveness Research Act of 2009 (H.R. 2502) Patient Centered Outcomes research Act of 2009 (S. 1213) Provisions related to comparative effectiveness reserach in S. 1679, the Affordable Health Choices Act; H.R. 3200 America's Affordable Health Choices Act of 2009; America's Healthy Futures Act of 2009
Comparative Effectiveness Research Act of 2009
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
Comparative Effectiveness Research Act of 2009 (H.R. 2502) Patient Centered Outcomes research Act of 2009 (S. 1213) Provisions related to comparative effectiveness reserach in S. 1679, the Affordable Health Choices Act; H.R. 3200 America's Affordable Health Choices Act of 2009; America's Healthy Futures Act of 2009
Comparative Effectiveness Research Act of 2009
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
Chronic disease and diabetes care related provisions in S. 1679, the Affordable Health Choices Act; America's Healthy Futures Act of 2009 (no bill number); H.R. 3200 America's Affordable Health Choices Act of 2009 H.R. 2502 Comparative Effectiveness Research Act of 2009 S. 1213 Patient Centered Outcomes Research Act of 2009 Provisions related to comparative effectiveness reserach and reimbursement in S. 1679, the Affordable Health Choices Act; America's Healthy Futures Act of 2009 (no bill number); H.R. 3200 America's Affordable Health Choices Act of 2009
America's Affordable Health Choices Act of 2009
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
Data exclusivity provisions in H.R. 1548, Pathway for Biosimilars Act Data eclsuivity provisions in Promoting Innovation and Access to Life-Saving Medicine Act (H.R. 1427,S. 726) Physician Payments Sunshine provision of H.R. 3200 America's Affordable Health Choices Act of 2009 FDA Risk Evaulation Mitigation Strategies (REMS) Drug Safety Communications Drug importation issues
America's Affordable Health Choices Act of 2009
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
Medicare provisions and Medicaid rebate issues in S. 1679, the Affordable Health Choices Act; America's Healthy Futures Act of 2009 (no bill number); H.R. 3200 America's Affordable Health Choices Act of 2009 H.R. 2502 Comparative Effectiveness Research Act of 2009 S. 1213 Patient Centered Outcomes Research Act of 2009 Provisions related to comparative effectiveness reserach and reimbursement in S. 1679, the Affordable Health Choices Act; America's Healthy Futures Act of 2009 (no bill number); H.R. 3200 America's Affordable Health Choices Act of 2009
America's Affordable Health Choices Act of 2009
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
Data exclusivity provisions in H.R. 1548, Pathway for Biosimilars Act Data eclsuivity provisions in Promoting Innovation and Access to Life-Saving Medicine Act (H.R. 1427,S. 726) Physician Payments Sunshine provision of H.R. 3200 America's Affordable Health Choices Act of 2009 FDA Risk Evaulation Mitigation Strategies (REMS) Drug Safety Communications Drug importation issues
America's Affordable Health Choices Act of 2009
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
Chronic disease and diabetes care related provisions in S. 1679, the Affordable Health Choices Act; America's Healthy Futures Act of 2009 (no bill number); H.R. 3200 America's Affordable Health Choices Act of 2009 H.R. 2502 Comparative Effectiveness Research Act of 2009 S. 1213 Patient Centered Outcomes Research Act of 2009 Provisions related to comparative effectiveness reserach and reimbursement in S. 1679, the Affordable Health Choices Act; America's Healthy Futures Act of 2009 (no bill number); H.R. 3200 America's Affordable Health Choices Act of 2009
America's Affordable Health Choices Act of 2009
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
Medicare provisions and Medicaid rebate issues in S. 1679, the Affordable Health Choices Act; America's Healthy Futures Act of 2009 (no bill number); H.R. 3200 America's Affordable Health Choices Act of 2009 H.R. 2502 Comparative Effectiveness Research Act of 2009 S. 1213 Patient Centered Outcomes Research Act of 2009 Provisions related to comparative effectiveness reserach and reimbursement in S. 1679, the Affordable Health Choices Act; America's Healthy Futures Act of 2009 (no bill number); H.R. 3200 America's Affordable Health Choices Act of 2009
America's Affordable Health Choices Act of 2009
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
Comparative Effectiveness Research Act of 2009 (H.R. 2502) Patient Centered Outcomes research Act of 2009 (S. 1213) Provisions related to comparative effectiveness reserach in S. 1679, the Affordable Health Choices Act; H.R. 3200 America's Affordable Health Choices Act of 2009; America's Healthy Futures Act of 2009
America's Affordable Health Choices Act of 2009
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
Physician Payments Sunshine provision of H.R. 3200 America's Affordable Health Choices Act of 2009 Physician Payments Sunshine provision of Affordable Health Care for America Act (H.R. 3962)- House Physician Payments Sunshine provision of Patient Protection and Affordable Care Act (H.R. 3590)-Senate FDA Risk Evaulation Mitigation Strategies (REMS) Drug Safety Communications Drug importation issues in the Affordable Health Care for America Act (H.R. 3962)- House and the Patient Protection and Affordable Care Act (H.R. 3590)-Senate
America's Affordable Health Choices Act of 2009
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
Comparative Effectiveness Research Act of 2009 (H.R. 2502) Patient Centered Outcomes research Act of 2009 (S. 1213) Provisions related to comparative effectiveness reserach in S. 1679, the Affordable Health Choices Act; H.R. 3200 America's Affordable Health Choices Act of 2009; America's Healthy Futures Act of 2009
America's Affordable Health Choices Act of 2009
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
Chronic disease and diabetes care related provisions in S. 1679, the Affordable Health Choices Act; America's Healthy Futures Act of 2009 (no bill number); H.R. 3200 America's Affordable Health Choices Act of 2009 H.R. 2502 Comparative Effectiveness Research Act of 2009 S. 1213 Patient Centered Outcomes Research Act of 2009 Provisions related to comparative effectiveness reserach and reimbursement in S. 1679, the Affordable Health Choices Act; America's Healthy Futures Act of 2009 (no bill number); H.R. 3200 America's Affordable Health Choices Act of 2009
Patient-Centered Outcomes Research Act of 2009
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
Chronic disease and diabetes care related provisions in S. 1679, the Affordable Health Choices Act; America's Healthy Futures Act of 2009 (no bill number); H.R. 3200 America's Affordable Health Choices Act of 2009 H.R. 2502 Comparative Effectiveness Research Act of 2009 S. 1213 Patient Centered Outcomes Research Act of 2009 Provisions related to comparative effectiveness reserach and reimbursement in S. 1679, the Affordable Health Choices Act; America's Healthy Futures Act of 2009 (no bill number); H.R. 3200 America's Affordable Health Choices Act of 2009
Patient-Centered Outcomes Research Act of 2009
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
Chronic disease and diabetes care related provisions in S. 1679, the Affordable Health Choices Act; America's Healthy Futures Act of 2009 (no bill number); H.R. 3200 America's Affordable Health Choices Act of 2009 H.R. 2502 Comparative Effectiveness Research Act of 2009 S. 1213 Patient Centered Outcomes Research Act of 2009 Provisions related to comparative effectiveness reserach and reimbursement in S. 1679, the Affordable Health Choices Act; America's Healthy Futures Act of 2009 (no bill number); H.R. 3200 America's Affordable Health Choices Act of 2009
Patient-Centered Outcomes Research Act of 2009
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
Medicare provisions and Medicaid rebate issues in S. 1679, the Affordable Health Choices Act; America's Healthy Futures Act of 2009 (no bill number); H.R. 3200 America's Affordable Health Choices Act of 2009 H.R. 2502 Comparative Effectiveness Research Act of 2009 S. 1213 Patient Centered Outcomes Research Act of 2009 Provisions related to comparative effectiveness reserach and reimbursement in S. 1679, the Affordable Health Choices Act; America's Healthy Futures Act of 2009 (no bill number); H.R. 3200 America's Affordable Health Choices Act of 2009
Patient-Centered Outcomes Research Act of 2009
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
Medicare provisions and Medicaid rebate issues in S. 1679, the Affordable Health Choices Act; America's Healthy Futures Act of 2009 (no bill number); H.R. 3200 America's Affordable Health Choices Act of 2009 H.R. 2502 Comparative Effectiveness Research Act of 2009 S. 1213 Patient Centered Outcomes Research Act of 2009 Provisions related to comparative effectiveness reserach and reimbursement in S. 1679, the Affordable Health Choices Act; America's Healthy Futures Act of 2009 (no bill number); H.R. 3200 America's Affordable Health Choices Act of 2009
Patient-Centered Outcomes Research Act of 2009
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
Comparative Effectiveness Research Act of 2009 (H.R. 2502) Patient Centered Outcomes research Act of 2009 (S. 1213) Provisions related to comparative effectiveness reserach in S. 1679, the Affordable Health Choices Act; H.R. 3200 America's Affordable Health Choices Act of 2009; America's Healthy Futures Act of 2009
Patient-Centered Outcomes Research Act of 2009
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
Comparative Effectiveness Research Act of 2009 (H.R. 2502) Patient Centered Outcomes research Act of 2009 (S. 1213) Provisions related to comparative effectiveness reserach in S. 1679, the Affordable Health Choices Act; H.R. 3200 America's Affordable Health Choices Act of 2009; America's Healthy Futures Act of 2009
Chronic disease and diabetes care related provisions in S. 1679, the Affordable Health Choices Act; America's Healthy Futures Act of 2009 (no bill number); H.R. 3200 America's Affordable Health Choices Act of 2009 H.R. 2502 Comparative Effectiveness Research Act of 2009 S. 1213 Patient Centered Outcomes Research Act of 2009 Provisions related to comparative effectiveness reserach and reimbursement in S. 1679, the Affordable Health Choices Act; America's Healthy Futures Act of 2009 (no bill number); H.R. 3200 America's Affordable Health Choices Act of 2009
Medicare provisions and Medicaid rebate issues in S. 1679, the Affordable Health Choices Act; America's Healthy Futures Act of 2009 (no bill number); H.R. 3200 America's Affordable Health Choices Act of 2009 H.R. 2502 Comparative Effectiveness Research Act of 2009 S. 1213 Patient Centered Outcomes Research Act of 2009 Provisions related to comparative effectiveness reserach and reimbursement in S. 1679, the Affordable Health Choices Act; America's Healthy Futures Act of 2009 (no bill number); H.R. 3200 America's Affordable Health Choices Act of 2009
Comparative Effectiveness Research Act of 2009 (H.R. 2502) Patient Centered Outcomes research Act of 2009 (S. 1213) Provisions related to comparative effectiveness reserach in S. 1679, the Affordable Health Choices Act; H.R. 3200 America's Affordable Health Choices Act of 2009; America's Healthy Futures Act of 2009
Comparative Effectiveness Research Act of 2009 (H.R. 2502) Patient Centered Outcomes research Act of 2009 (S. 1213) Provisions related to comparative effectiveness reserach in S. 1679, the Affordable Health Choices Act; H.R. 3200 America's Affordable Health Choices Act of 2009; America's Healthy Futures Act of 2009
Medicare provisions and Medicaid rebate issues in S. 1679, the Affordable Health Choices Act; America's Healthy Futures Act of 2009 (no bill number); H.R. 3200 America's Affordable Health Choices Act of 2009 H.R. 2502 Comparative Effectiveness Research Act of 2009 S. 1213 Patient Centered Outcomes Research Act of 2009 Provisions related to comparative effectiveness reserach and reimbursement in S. 1679, the Affordable Health Choices Act; America's Healthy Futures Act of 2009 (no bill number); H.R. 3200 America's Affordable Health Choices Act of 2009
Chronic disease and diabetes care related provisions in S. 1679, the Affordable Health Choices Act; America's Healthy Futures Act of 2009 (no bill number); H.R. 3200 America's Affordable Health Choices Act of 2009 H.R. 2502 Comparative Effectiveness Research Act of 2009 S. 1213 Patient Centered Outcomes Research Act of 2009 Provisions related to comparative effectiveness reserach and reimbursement in S. 1679, the Affordable Health Choices Act; America's Healthy Futures Act of 2009 (no bill number); H.R. 3200 America's Affordable Health Choices Act of 2009
Exclusivity, and damanges provisions in the Patent Reform Act of 2009 (S. 515, H.R. 1260)
Exclusivity, damanges and estoppel provisions in the Patent Reform Act of 2009 (S. 515, H.R. 1260)
Exclusivity, and damanges provisions in the Patent Reform Act of 2009 (S. 515, H.R. 1260)
Promoting Innovation and Access to Life-Saving Medicine Act
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
Data exclusivity provisions in H.R. 1548, Pathway for Biosimilars Act Data eclsuivity provisions in Promoting Innovation and Access to Life-Saving Medicine Act (H.R. 1427,S. 726) Physician Payments Sunshine provision of H.R. 3200 America's Affordable Health Choices Act of 2009 FDA Risk Evaulation Mitigation Strategies (REMS) Drug Safety Communications Drug importation issues
Promoting Innovation and Access to Life-Saving Medicine Act
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
Data exclusivity provisions in H.R. 1548, Pathway for Biosimilars Act Data eclsuivity provisions in Promoting Innovation and Access to Life-Saving Medicine Act (H.R. 1427,S. 726) Physician Payments Sunshine provision of H.R. 3200 America's Affordable Health Choices Act of 2009 FDA Risk Evaulation Mitigation Strategies (REMS) Drug Safety Communications Drug importation issues
American Middle Class Tax (AMT) Relief Act of 2007
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
Chronic disease and diabetes care related provisions in Affordable Health Care for America Act (H.R. 3962)- House and the Patient Protection and Affordable Care Act (H.R. 3590)-Senate Provisions related to comparative effectiveness reserach and reimbursement in the Affordable Health Care for America Act (H.R. 3962)- House and the Patient Protection and Affordable Care Act (H.R. 3590)-Senate
American Middle Class Tax (AMT) Relief Act of 2007
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
Provisions related to comparative effectiveness reserach in the Affordable Health Care for America Act (H.R. 3962)- House and the Patient Protection and Affordable Care Act (H.R. 3590)-Senate
American Middle Class Tax (AMT) Relief Act of 2007
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
Physician Payments Sunshine provision of H.R. 3200 America's Affordable Health Choices Act of 2009 Physician Payments Sunshine provision of Affordable Health Care for America Act (H.R. 3962)- House Physician Payments Sunshine provision of Patient Protection and Affordable Care Act (H.R. 3590)-Senate FDA Risk Evaulation Mitigation Strategies (REMS) Drug Safety Communications Drug importation issues in the Affordable Health Care for America Act (H.R. 3962)- House and the Patient Protection and Affordable Care Act (H.R. 3590)-Senate
American Middle Class Tax (AMT) Relief Act of 2007
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
Provisions related to the expansion of Medicaid rebates in the Affordable Health Care for America Act (H.R. 3962)- House and the Patient Protection and Affordable Care Act (H.R. 3590)-Senate Provisions related to the expansion of Medicaid eligibility in the Affordable Health Care for America Act (H.R. 3962)- House and the Patient Protection and Affordable Care Act (H.R. 3590)-Senate Provisions related to Medicare Part D in the Affordable Health Care for America Act (H.R. 3962)- House and the Patient Protection and Affordable Care Act (H.R. 3590)-Senate
Provisions related to the expansion of Medicaid rebates in the Affordable Health Care for America Act (H.R. 3962)- House and the Patient Protection and Affordable Care Act (H.R. 3590)-Senate Provisions related to the expansion of Medicaid eligibility in the Affordable Health Care for America Act (H.R. 3962)- House and the Patient Protection and Affordable Care Act (H.R. 3590)-Senate Provisions related to Medicare Part D in the Affordable Health Care for America Act (H.R. 3962)- House and the Patient Protection and Affordable Care Act (H.R. 3590)-Senate
Provisions related to comparative effectiveness reserach in the Affordable Health Care for America Act (H.R. 3962)- House and the Patient Protection and Affordable Care Act (H.R. 3590)-Senate
Physician Payments Sunshine provision of H.R. 3200 America's Affordable Health Choices Act of 2009 Physician Payments Sunshine provision of Affordable Health Care for America Act (H.R. 3962)- House Physician Payments Sunshine provision of Patient Protection and Affordable Care Act (H.R. 3590)-Senate FDA Risk Evaulation Mitigation Strategies (REMS) Drug Safety Communications Drug importation issues in the Affordable Health Care for America Act (H.R. 3962)- House and the Patient Protection and Affordable Care Act (H.R. 3590)-Senate
Chronic disease and diabetes care related provisions in Affordable Health Care for America Act (H.R. 3962)- House and the Patient Protection and Affordable Care Act (H.R. 3590)-Senate Provisions related to comparative effectiveness reserach and reimbursement in the Affordable Health Care for America Act (H.R. 3962)- House and the Patient Protection and Affordable Care Act (H.R. 3590)-Senate
Perscription Drug User Fee Act Reauthorization FDA funding and agency effectiveness Drug importation issues Safeguarding America's Pharmaceuticals Act of 2011- H.R. 3026
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMYLIN PHARMACEUTICALS via AMYLIN PHARMACEUTICALS
2012 · second_quarter · Q2
Issues relating to Medicare Part D rebates
Perscription Drug User Fee Act Reauthorization FDA funding and agency effectiveness Drug importation issues Safeguarding America's Pharmaceuticals Act of 2011- H.R. 3026
Issues related to prevention, diagnosis and treatment of diabetes
FDA funding and agency effectiveness Potential Super Committee legislation affecting Medciare Part D and Medicaid rebates
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMYLIN PHARMACEUTICALS via AMYLIN PHARMACEUTICALS
2012 · first_quarter · Q1
Issues relating to Medicare Part D rebates
Issues related to prevention, diagnosis and treatment of diabetes
Perscription Drug User Fee Act Reauthorization FDA funding and agency effectiveness Drug importation issues Safeguarding America's Pharmaceuticals Act of 2011- H.R. 3026
FDA funding and agency effectiveness Potential Super Committee legislation affecting Medciare Part D and Medicaid rebates
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMYLIN PHARMACEUTICALS via AMYLIN PHARMACEUTICALS
2011 · fourth_quarter · Q4
FDA funding and agency effectiveness Potential Super Committee legislation affecting Medciare Part D and Medicaid rebates
Issues relating to Medicare Part D rebates
Issues related to prevention, diagnosis and treatment of diabetes
Perscription Drug User Fee Act Reauthorization FDA funding and agency effectiveness Drug importation issues Safeguarding America's Pharmaceuticals Act of 2011- H.R. 3026
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMYLIN PHARMACEUTICALS via AMYLIN PHARMACEUTICALS
2011 · third_quarter · Q3
Issues related to the America Invents Act (S. 23, H.R. 1249)
FDA funding and agency effectiveness Potential Super Committee legislation affecting Medciare Part D and Medicaid rebates
Issues related to prevention, diagnosis and treatment of diabetes
Perscription Drug User Fee Act reauthorization FDA funding and agency effectiveness Drug importation issues Safeguarding America's Pharmaceuticals Act of 2011- H.R. 3026
Issues relating to Medicare Part D rebates
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMYLIN PHARMACEUTICALS via AMYLIN PHARMACEUTICALS
2011 · second_quarter · Q2
Provisions related to comparative effectiveness research in HR 3590 Pub. L. 111-148 (Patient Protection and Affordable Care Act of 2010)
FDA funding and agency effectiveness
Provisions related to the expansion of Medicaid rebates in Pub. L. 111-148 (Patient Protection and Affordable Care Act of 2010) Provisions related to the expansion of Medicaid eligibility in Pub. L. 111-148 (Patient Protection and Affordable Care Act of 2010) Provisions related to Medicare Part D rebates Pub. L. 111-148 (Patient Protection and Affordable Care Act of 2010) Medicare and Medicaid provisions of H.R. 4213, American Jobs and Closing Tax Loopholes Act of 2010
AMYLIN PHARMACEUTICALS via AMYLIN PHARMACEUTICALS
2011 · first_quarter · Q1
FDA funding and agency effectiveness
Exclusivity, damages, estoppel, post grant review and inter partes review provisions in the America Invents Act (S. 23, H.R. 1249)
Perscription Drug User Fee Act reauthorization FDA funding and agency effectiveness Drug importation issues
AMYLIN PHARMACEUTICALS via AMYLIN PHARMACEUTICALS
2010 · fourth_quarter · Q4
Drug importation issues
Comparative effectiveness research and reimbursement in Pub. L. 111-148 (Patient Protection and Affordable Care Act of 2010)
Provisions related to the expansion of Medicaid rebates in Pub. L. 111-148 (Patient Protection and Affordable Care Act of 2010) Provisions related to the expansion of Medicaid eligibility in Pub. L. 111-148 (Patient Protection and Affordable Care Act of 2010) Provisions related to Medicare Part D rebates Pub. L. 111-148 (Patient Protection and Affordable Care Act of 2010) Medicare and Medicaid provisions of H.R. 4213, American Jobs and Closing Tax Loopholes Act of 2010
AMYLIN PHARMACEUTICALS via AMYLIN PHARMACEUTICALS
2010 · third_quarter · Q3
Exclusivity, damages and estoppel provisions in the Patent Reform Act of 2009 (S. 515, H.R. 1260)
Health care reform issues in H.R. 4872 Health Care Education and Reconciliation Act of 2010 related to Pub. L. 111-148 (Patient Protection and Affordable Care Act of 2010)
Prescription drug issues Chronic disease and diabetes treatment issues within the Veterans Administration
AMYLIN PHARMACEUTICALS via AMYLIN PHARMACEUTICALS
2010 · second_quarter · Q2
Exclusivity, damages and estoppel provisions in the Patent Reform Act of 2009 (S. 515, H.R. 1260)
Prescription drug issues Chronic disease and diabetes treatment issues within the Veterans Administration
Provisions related to the expansion of Medicaid rebates in Pub. L. 111-148 (Patient Protection and Affordable Care Act of 2010) Provisions related to the expansion of Medicaid eligibility in Pub. L. 111-148 (Patient Protection and Affordable Care Act of 2010) Provisions related to Medicare Part D rebates Pub. L. 111-148 (Patient Protection and Affordable Care Act of 2010) Medicare and Medicaid provisions of H.R. 4213, American Jobs and Closing Tax Loopholes Act of 2010
AMYLIN PHARMACEUTICALS via AMYLIN PHARMACEUTICALS
2010 · first_quarter · Q1
Physician Payments Sunshine provision of HR 3590 the Patient Protection and Affordable Care Act and H.R.4872 the Health Care and Education Reconciliation Act of 2010 FDA Risk Evaulation Mitigation Strategies (REMS) Drug Safety Communications Drug importation issues in HR 3590 the Patient Protection and Affordable Care Act and H.R.4872 the Health Care and Education Reconciliation Act of 2010
Provisions related to the expansion of Medicaid rebates in HR 3590 the Patient Protection and Affordable Care Act and H.R.4872 the Health Care and Education Reconciliation Act of 2010 Provisions related to the expansion of Medicaid eligibility in HR 3590 the Patient Protection and Affordable Care Act and H.R.4872 the Health Care and Education Reconciliation Act of 2010 Provisions related to Medicare Part D rebates in HR 3590 the Patient Protection and Affordable Care Act and H.R.4872 the Health Care and Education Reconciliation Act of 2010
AMYLIN PHARMACEUTICALS via AMYLIN PHARMACEUTICALS
2009 · fourth_quarter · Q4
Provisions related to comparative effectiveness reserach in the Affordable Health Care for America Act (H.R. 3962)- House and the Patient Protection and Affordable Care Act (H.R. 3590)-Senate
Chronic disease and diabetes care related provisions in Affordable Health Care for America Act (H.R. 3962)- House and the Patient Protection and Affordable Care Act (H.R. 3590)-Senate Provisions related to comparative effectiveness reserach and reimbursement in the Affordable Health Care for America Act (H.R. 3962)- House and the Patient Protection and Affordable Care Act (H.R. 3590)-Senate
AMYLIN PHARMACEUTICALS via AMYLIN PHARMACEUTICALS
2009 · third_quarter · 3A
Chronic disease and diabetes care related provisions in S. 1679, the Affordable Health Choices Act; America's Healthy Futures Act of 2009 (no bill number); H.R. 3200 America's Affordable Health Choices Act of 2009 H.R. 2502 Comparative Effectiveness Research Act of 2009 S. 1213 Patient Centered Outcomes Research Act of 2009 Provisions related to comparative effectiveness reserach and reimbursement in S. 1679, the Affordable Health Choices Act; America's Healthy Futures Act of 2009 (no bill number); H.R. 3200 America's Affordable Health Choices Act of 2009
Medicare provisions and Medicaid rebate issues in S. 1679, the Affordable Health Choices Act; America's Healthy Futures Act of 2009 (no bill number); H.R. 3200 America's Affordable Health Choices Act of 2009 H.R. 2502 Comparative Effectiveness Research Act of 2009 S. 1213 Patient Centered Outcomes Research Act of 2009 Provisions related to comparative effectiveness reserach and reimbursement in S. 1679, the Affordable Health Choices Act; America's Healthy Futures Act of 2009 (no bill number); H.R. 3200 America's Affordable Health Choices Act of 2009
AMYLIN PHARMACEUTICALS via AMYLIN PHARMACEUTICALS
2009 · third_quarter · Q3
Exclusivity, and damanges provisions in the Patent Reform Act of 2009 (S. 515, H.R. 1260)
Data exclusivity provisions in H.R. 1548, Pathway for Biosimilars Act Data eclsuivity provisions in Promoting Innovation and Access to Life-Saving Medicine Act (H.R. 1427,S. 726) Physician Payments Sunshine provision of H.R. 3200 America's Affordable Health Choices Act of 2009 FDA Risk Evaulation Mitigation Strategies (REMS) Drug Safety Communications Drug importation issues
Chronic disease and diabetes care related provisions in S. 1679, the Affordable Health Choices Act; America's Healthy Futures Act of 2009 (no bill number); H.R. 3200 America's Affordable Health Choices Act of 2009 H.R. 2502 Comparative Effectiveness Research Act of 2009 S. 1213 Patient Centered Outcomes Research Act of 2009 Provisions related to comparative effectiveness reserach and reimbursement in S. 1679, the Affordable Health Choices Act; America's Healthy Futures Act of 2009 (no bill number); H.R. 3200 America's Affordable Health Choices Act of 2009
Prevention, diagnosis and treatment of diabetes Diabetes issues related to implementation of provisions of Pub. L. 111-148 (Patient Protection and Affordable Care Act of 2010)
Exclusivity, damages,estoppel, post grant review and inter partes review provisions in the America Invents Act (S. 23, H.R. 1249)
Perscription Drug User Fee Act reauthorization FDA funding and agency effectiveness Drug importation issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Prevention, diagnosis and treatment of diabetes Diabetes issues related to implementation of provisions of Pub. L. 111-148 (Patient Protection and Affordable Care Act of 2010)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Exclusivity, damages and estoppel provisions in the Patent Reform Act of 2009 (S. 515, H.R. 1260)
Prescription drug issues Chronic disease and diabetes treatment issues within the Veterans Administration
Provisions related to comparative effectiveness research in HR 3590 Pub. L. 111-148 (Patient Protection and Affordable Care Act of 2010)
Health care reform issues in H.R. 4872 Health Care Education and Reconciliation Act of 2010 related to Pub. L. 111-148 (Patient Protection and Affordable Care Act of 2010)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Provisions related to the expansion of Medicaid rebates in Pub. L. 111-148 (Patient Protection and Affordable Care Act of 2010) Provisions related to the expansion of Medicaid eligibility in Pub. L. 111-148 (Patient Protection and Affordable Care Act of 2010) Provisions related to Medicare Part D rebates Pub. L. 111-148 (Patient Protection and Affordable Care Act of 2010) Medicare and Medicaid provisions of H.R. 4213, American Jobs and Closing Tax Loopholes Act of 2010
Comparative effectiveness research and reimbursement in Pub. L. 111-148 (Patient Protection and Affordable Care Act of 2010)
Provisions related to comparative effectiveness research in HR 3590 Pub. L. 111-148 (Patient Protection and Affordable Care Act of 2010)
Drug importation issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Provisions related to comparative effectiveness research in HR 3590 Pub. L. 111-148 (Patient Protection and Affordable Care Act of 2010)
Chronic disease and diabetes care related provisions in Pub. L. 111-148 (Patient Protection and Affordable Care Act of 2010) Provisions related to comparative effectiveness reserach and reimbursement in Pub. L. 111-148 (Patient Protection and Affordable Care Act of 2010)
Physician Payments Sunshine provision of Pub. L. 111-148 (Patient Protection and Affordable Care Act of 2010) FDA Risk Evaulation Mitigation Strategies (REMS) Drug Safety Communications Drug importation issues
Health care reform issues in H.R. 4872 Health Care Education and Reconciliation Act of 2010 related to Pub. L. 111-148 (Patient Protection and Affordable Care Act of 2010)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Chronic disease and diabetes care related provisions in HR 3590 the Patient Protection and Affordable Care Act and H.R.4872 the Health Care and Education Reconciliation Act of 2010 Provisions related to comparative effectiveness reserach and reimbursement HR 3590 the Patient Protection and Affordable Care Act and H.R.4872 the Health Care and Education Reconciliation Act of 2010
Provisions related to comparative effectiveness research in HR 3590 the Patient Protection and Affordable Care Act and H.R.4872 the Health Care and Education Reconciliation Act of 2010
Exclusivity, damages and estoppel provisions in the Patent Reform Act of 2009 (S. 515, H.R. 1260)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Comparative effectiveness provisions in the American Recovery and Reinvestment Act (H.R. 1)
Exclusivity, damanges and estoppel provisions in the Patent Reform Act of 2009 (S. 515, H.R. 1260)
Provisions related to the expansion of Medicaid rebates in the Affordable Health Care for America Act (H.R. 3962)- House and the Patient Protection and Affordable Care Act (H.R. 3590)-Senate Provisions related to the expansion of Medicaid eligibility in the Affordable Health Care for America Act (H.R. 3962)- House and the Patient Protection and Affordable Care Act (H.R. 3590)-Senate Provisions related to Medicare Part D in the Affordable Health Care for America Act (H.R. 3962)- House and the Patient Protection and Affordable Care Act (H.R. 3590)-Senate
Physician Payments Sunshine provision of H.R. 3200 America's Affordable Health Choices Act of 2009 Physician Payments Sunshine provision of Affordable Health Care for America Act (H.R. 3962)- House Physician Payments Sunshine provision of Patient Protection and Affordable Care Act (H.R. 3590)-Senate FDA Risk Evaulation Mitigation Strategies (REMS) Drug Safety Communications Drug importation issues in the Affordable Health Care for America Act (H.R. 3962)- House and the Patient Protection and Affordable Care Act (H.R. 3590)-Senate
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
Data exclusivity provisions in H.R. 1548, Pathway for Biosimilars Act Data eclsuivity provisions in Promoting Innovation and Access to Life-Saving Medicine Act (H.R. 1427,S. 726) Physician Payments Sunshine provision of H.R. 3200 America's Affordable Health Choices Act of 2009 FDA Risk Evaulation Mitigation Strategies (REMS) Drug Safety Communications Drug importation issues
Exclusivity, and damanges provisions in the Patent Reform Act of 2009 (S. 515, H.R. 1260)
Comparative Effectiveness Research Act of 2009 (H.R. 2502) Patient Centered Outcomes research Act of 2009 (S. 1213) Provisions related to comparative effectiveness reserach in S. 1679, the Affordable Health Choices Act; H.R. 3200 America's Affordable Health Choices Act of 2009; America's Healthy Futures Act of 2009
Comparative effectiveness provisions in the American Recovery and Reinvestment Act (H.R. 1)
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
Medicare provisions and Medicaid rebate issues in S. 1679, the Affordable Health Choices Act; America's Healthy Futures Act of 2009 (no bill number); H.R. 3200 America's Affordable Health Choices Act of 2009 H.R. 2502 Comparative Effectiveness Research Act of 2009 S. 1213 Patient Centered Outcomes Research Act of 2009 Provisions related to comparative effectiveness reserach and reimbursement in S. 1679, the Affordable Health Choices Act; America's Healthy Futures Act of 2009 (no bill number); H.R. 3200 America's Affordable Health Choices Act of 2009
Comparative effectiveness provisions in the American Recovery and Reinvestment Act (H.R. 1)
Comparative Effectiveness Research Act of 2009 (H.R. 2502) Patient Centered Outcomes research Act of 2009 (S. 1213) Provisions related to comparative effectiveness reserach in S. 1679, the Affordable Health Choices Act; H.R. 3200 America's Affordable Health Choices Act of 2009; America's Healthy Futures Act of 2009
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE